PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28278708-0	2017	Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide.	Lenalidomide	188-200	Janus kinase 2	Homo sapiens	54-58	
25189730-5	2014	The rationale of combination of danazol or lenalidomide with ruxolitinib is mainly based on mitigation of anti-JAK2-mediated myelosuppression.	Lenalidomide	43-55	Janus kinase 2	Homo sapiens	111-115	
27538006-0	2016	Erythema Nodosum-like Septal Panniculitis Secondary to Lenalidomide Therapy in a Patient With Janus Kinase 2-Positive Myelofibrosis.	Lenalidomide	55-67	Janus kinase 2	Homo sapiens	94-108	
27538006-2	2016	We present a case of a 66-year-old gentleman with JAK2-positive myelofibrosis who developed transient EN-like lesions on his trunk and upper and lower extremities approximately three weeks after starting lenalidomide therapy.	Lenalidomide	204-216	Janus kinase 2	Homo sapiens	50-54	
25963624-0	2015	Effectiveness of lenalidomide in a patient with refractory anemia with ring sideroblasts and thrombocytosis with JAK2 (V617F) mutation.	Lenalidomide	17-29	Janus kinase 2	Homo sapiens	113-117	
25469886-6	2014	Lenalidomide treatment rapidly induced lipid raft formation accompanied by EpoR recruitment into raft fractions together with STAT5, JAK2, and Lyn kinase.	Lenalidomide	0-12	Janus kinase 2	Homo sapiens	133-137	
25469886-8	2014	Lenalidomide treatment prior to Epo stimulation enhanced both JAK2 and STAT5 phosphorylation in UT7 and primary MDS erythroid progenitors, accompanied by increased STAT5 DNA binding in UT7 cells, and increased erythroid colony forming capacity in both UT7 and primary cells.	Lenalidomide	0-12	Janus kinase 2	Homo sapiens	62-66	
24966686-0	2014	Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy.	Lenalidomide	113-125	Janus kinase 2	Homo sapiens	61-71	
28801515-0	2017	Lenalidomide-associated arterial thrombosis in a patient with JAK2 positive atypical myeloproliferative neoplasm.	Lenalidomide	0-12	Janus kinase 2	Homo sapiens	62-66	
27330758-0	2016	Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment.	Lenalidomide	20-32	Janus kinase 2	Homo sapiens	117-121	
27330758-10	2016	The present case highlights the coexistence of the JAK2 V617F mutation in del(5q) MDS and suggests that lenalidomide treatment is beneficial and effective for these patients, leading to complete hematological, cytogenetic and molecular response.	Lenalidomide	104-116	Janus kinase 2	Homo sapiens	51-55	
23252419-0	2013	Response to lenalidomide of a patient with t(2;3)(p23;q29) and JAK2 non-mutated refractory anemia with ring sideroblasts and thrombocytosis.	Lenalidomide	12-24	Janus kinase 2	Homo sapiens	63-67	
20194893-0	2010	Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.	Lenalidomide	25-37	Janus kinase 2	Homo sapiens	55-59	
16990762-0	2006	Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.	Lenalidomide	40-52	Janus kinase 2	Homo sapiens	104-114	
20846100-0	2010	Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.	Lenalidomide	12-24	Janus kinase 2	Homo sapiens	94-98